<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154840</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HGCL009</org_study_id>
    <nct_id>NCT03154840</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Among Different Eutropin Formulations</brief_title>
  <official_title>A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Compares and evaluates the relative bioavailability of single-dose subcutaneous
           administration of each of the Eutropin formulations to healthy male volunteers.

        2. Ensure safety and tolerability of single, subcutaneous administration of Eutropin
           formulations to healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">July 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>6x3 Crossover Study</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of somatropin</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacokinetic assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of somatropin</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacokinetic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUCinf) of somatropin</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacokinetic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which the Cmax is observed (Tmax) of somatropin</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacokinetic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life time (t1/2Î²) of somatropin</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacokinetic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacodynamic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-BP3</measure>
    <time_frame>Total three period at weekly intervals (Week 1, Week2, Week3)</time_frame>
    <description>Pharmacodynamic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of adverse reactions</measure>
    <time_frame>Week -4(Screening), Week 1, Week 2, Week 3, Week 5</time_frame>
    <description>Clinical significance is assessed by reviewing the general findings of individual subjects individually, and when there is a specific or tendency, analysis is conducted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Week -4(Screening), Week 1, Week 2, Week 3, Week 5</time_frame>
    <description>Weight, Height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Week -4(Screening), Week 1, Week 2, Week 3, Week 5</time_frame>
    <description>Left-sided blood pressure (systolic / diastolic), pulse rate, tympanic temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Week -4(Screening), Week 1, Week 2, Week 3, Week 5</time_frame>
    <description>Ventricular rate, PR interval, QRS, QT/QTc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory test</measure>
    <time_frame>Week -4(Screening), Week 1, Week 2, Week 3, Week 5</time_frame>
    <description>General blood test, general chemical test, clinical chemistry urinalysis, pancreas test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection site reaction and Pain scale evaluation</measure>
    <time_frame>Week 1, Week 2, Week 3</time_frame>
    <description>Ask the NRS about the degree of pain and evaluate it as 0-10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Relative Bioavailability</condition>
  <arm_group>
    <arm_group_label>Eutropin 4IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eutropin AQ 12IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eutropin Pen 36IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU</intervention_name>
    <description>Investigate the Relative Bioavailability among Different Eutropin Formulations</description>
    <arm_group_label>Eutropin 4IU</arm_group_label>
    <arm_group_label>Eutropin AQ 12IU</arm_group_label>
    <arm_group_label>Eutropin Pen 36IU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A healthy male who is at least 19 years old but under 40 years of age at screening
             visit

          2. Those who weigh more than 50 kg at screening visit and whose body mass index (BMI) is
             greater than 19 kg / m2 but less than 28 kg / m2

          3. The result of the vital signs in the screening period.

          4. A person who is judged to be clinically insignificant in terms of physical or mental
             condition when the examinee medically judges the screening period physical examination

          5. Those who are not clinically significant when the examiner has medically judged the
             results of examination other than the items described in 17) and 18) of the exclusion
             criterion in the diagnosis laboratory test results in the screening period

          6. A person who consents to use a combination of effective contraceptive methods or
             medically appropriate contraceptive methods from the first administration of the
             clinical trial drug to the fourth administration (28 days) after the last
             administration of the drug for clinical trial and not to provide sperm

          7. Those who voluntarily decide to participate in clinical trials and observe the test
             subjects' precautions and agree in writing

        Exclusion Criteria:

          1. Those who with a history or history of diabetes

          2. Those who with a history or history of malignancy

          3. Those who with a history or history of musculoskeletal disorders (including epiphyseal
             closure, scoliosis, etc.)

          4. Those who with history or history of endocrine system (including hypothyroidism,
             panhypopituitarism, etc.)

          5. Those who have a history of skin disease, including psoriasis and contact dermatitis,
             or who can not exclude the possibility of skin disease under the judgment of the
             examiner on physical examination conducted at the screening visit.

          6. Exclusion Criteria In addition to items 1) to 5), there are other clinically
             significant history or history of liver, kidney, digestive system, respiratory system,
             neuropsychiatry, blood /

          7. Persons with a history of somatropin and octreotide acetate or hypersensitivity
             reactions to cresol, glycerol or other drugs (non-steroidal anti-inflammatory drugs,
             antibiotics, etc.)

          8. Those who have participated in other clinical trials or bioequivalence tests within 90
             days of the screening visit date

          9. Within 60 days before screening visit Those who have received blood (blood, whole
             blood, etc.) or blood transfusions

         10. Those who ingest herbal medicines or health functional foods within 14 days before the
             screening visit or those who are expected to affect the clinical trial within 7 days

         11. Within 14 days prior to screening visit, special medicines that may affect the
             clinical trial, or those who use general medicines within 7 days

         12. Screening Within 30 days prior to the visiting date Alcohol Abuse (alcohol-containing
             beverage&gt; 21 units / week)

         13. Over 30 days before screening visit Overcame smoker (cigarette&gt; 10 cigarettes / day)

         14. Within 7 days of screening visit Caffeine-containing foods Excessive intake
             (caffeinated foods&gt; 3 times / week)

         15. Screening Within 7 days prior to the visit Date of intake of food containing xanthine

         16. As a result of urine nicotine test or urine drug screening test during the screening
             period

         17. Screening period serum test (hepatitis B test, human immunodeficiency virus (HIV)
             test, hepatitis C test, syphilis test) Result positive

         18. Diagnosis of Screening Period In the case of a laboratory test, one or more of the
             following findings

               -  Fasting glucose&gt; 110 mg / dL

               -  TSH Reference Range Above upper limit or below lower limit

               -  IGF-1 and IGFBP-3 according to the age of the test subjects. Reference range
                  Above upper limit or below lower limit

               -  Vitamin B12 Reference range above or below the upper limit

               -  Insulin reference range above or below the upper limit

               -  More than twice the AST or ALT or Alkaline Phosphatase (ALP) reference range
                  upper limit

               -  More than 1.5 times the upper limit of the bilirubin total reference range

         19. A 12-electrode electrocardiogram in the screening period revealed a QTc&gt; 450 ms or
             clinically significant abnormalities

         20. Those who are judged to be inadequate to perform the clinical trial when the examiners
             judge them for other reasons
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Malignancy Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

